RxDoctor Payments Data

David Chandler, MD

Ophthalmology · Mechanicsville, VANPI 1740275213

Payments from drug & device makers

$2,431in general payments, 2019–2025

Across 96 payments — averaging $25.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$990
  • Sun Pharmaceutical Industries Inc.$403
  • Bausch & Lomb Americas Inc.$218
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$143
  • Alcon$131
  • Amgen$104
  • plus $442 from 9 others

What the payments were for

  • Food & beverage$2,41199%
  • Gifts$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,431 in reported general payments places this provider in the 65th percentile of 509 ophthalmology providers in Virginia.

See all ophthalmology providers in Virginia

Medicare billing

Part B allowed, 2024
$262,024
Medicare patients
785
Services billed
2,439

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyzultaLatanoprostene Bunod20$12,352
LumiganBimatoprost19$8,424
Prednisolone Acetate237$7,574
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha460$4,976
Latanoprost409$4,335
Ketorolac Tromethamine223$3,430
Travoprost20$2,627
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat154$2,160
Ofloxacin152$1,729
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol14$1,479
Brimonidine Tartrate132$1,248
Timolol Maleate147$1,233
Fluorometholone12$512
Dorzolamide Hcl32$506
ErythromycinErythromycin Base57$465

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Vyzulta$218$12,35220 claims
AbbVieLumigan$990$8,42419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 509 ophthalmology providers in Virginia.

Other ophthalmology in Mechanicsville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →